CD8A and neoplasm: Lately, the tumour immune status, such as cold or hot tumours, has garnered substantial attention as a predictive biomarker and therapeutic target to enhance the ICI sensitivity.40 Hot tumours with high PD-L1 expression and high CD8+TILs correlate with the high sensitivity of immune checkpoint blockades.